Paralysed Zenotech awaits Daiichi Sankyo booster dose
This article was originally published in Scrip
Executive Summary
About five years since the Indian firm, Zenotech Laboratories, changed hands to Ranbaxy Laboratories and then indirectly to Daiichi Sankyo as a result of Ranbaxy's acquisition by the Japanese giant, intra-management disagreements appear to have near paralysed activity at the once promising biotech firm.